Holen Sie sich die Stockscreener-App
0.93
2.09%
-0.0199
Schlusskurs vom Vortag:
$0.9499
Offen:
$0.94
24-Stunden-Volumen:
146.46K
Relative Volume:
0.12
Marktkapitalisierung:
$14.69M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.54M
KGV:
-0.7115
EPS:
-1.3071
Netto-Cashflow:
$-21.18M
1W Leistung:
-3.67%
1M Leistung:
-0.16%
6M Leistung:
-84.10%
1J Leistung:
-42.59%
1-Tages-Spanne:
$0.8861
$0.9499
1-Wochen-Bereich:
$0.87
$1.09
52-Wochen-Spanne:
$0.4606
$7.20
Calcimedica Inc Stock (CALC) Company Profile
Firmenname
Calcimedica Inc
Sektor
Branche
Telefon
858-952-5500
Adresse
505 COAST BOULEVARD SOUTH, LA JOLLA
Compare CALC vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CALC
Calcimedica Inc
|
0.93 | 14.69M | 0 | -19.54M | -21.18M | -1.3071 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Calcimedica Inc Stock (CALC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
Calcimedica Inc Aktie (CALC) Neueste Nachrichten
CalciMedica Stock Short Interest Rises to 33.91% - Quiver Quantitative
[Form 3] CalciMedica, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Alafi Capital Discloses Investment at CalciMedica with 17.1% Stake - TradingView
CalciMedica (CALC) gains 17.1% shareholder as Alafi Capital ups stake in $2.8M deal - Stock Titan
calcimedica inc glp-1 receptor agonists weight management diabetes treatments GLP-1 Receptor Agonists: antidiabetic and weight loss management drugs: A Complete Review - news36live
CalciMedica, Inc. Files Form 8-K with SEC: Key Company and Stock Information for July 2026 - Minichart
CALC Q1 2026 Earnings: Surprise Positive EPS Amidst Revenue AbsenceBook Value Growth - dars.gov.et
Form 4 CalciMedica Inc For: 7 July By Investing.com - Investing.com Nigeria
Director at CalciMedica (CALC) granted stock options on 20,000 shares - Stock Titan
CalciMedica (NASDAQ: CALC) director lists 2.1M shares and capped warrant holdings - Stock Titan
CalciMedica Announces Board Expansion and Leadership Transition - TipRanks
CalciMedica (NASDAQ: CALC) appoints Dr. Evgeny Zaytsev to board - Stock Titan
CalciMedica, Inc. Announces Board Changes, Effective July 2, 2026 - marketscreener.com
CALC Q1 2026 Earnings: Positive EPS Surprise Defies Expectations Amid Pre‑Revenue StatusPost-Earnings Reaction - dars.gov.et
CALCCalciMedica Inc Options - Finviz
CalciMedica (NASDAQ: CALC) gains 6.9% holder via June 2026 private placement - Stock Titan
Bering Partners II Discloses Investment at CalciMedica with 6.9% Stake - TradingView
Form 13D/A CALCIMEDICA For: 30 June By Investing.com - Investing.com Nigeria
CalciMedica (CALC) insiders add shares via open-market and unit purchases - Stock Titan
Form 4 CalciMedica Inc For: 29 June By Investing.com - Investing.com South Africa
Calcimedica director Fred Middleton acquires $199,999 in stock. - Investing.com
Calcimedica director Fred Middleton acquires $199,999 in stock. By Investing.com - Investing.com Australia
CalciMedica (CALC) chief business officer gets 186,729-share stock award at $0.8033 - Stock Titan
CalciMedica (CALC) insider-affiliated fund buys 248,972 new shares at $0.8033 - Stock Titan
FDA raises no concerns over Auxora safety data, CalciMedica advances trial - MSN
CalciMedica (NASDAQ: CALC) lenders capped at 4.99% ownership after loan amendment - Stock Titan
Key facts: CalciMedica $15M raise; Auxora paused, FDA feedback due Q3 - TradingView
CalciMedica Receives FDA Clearance to Resume Auxora Clinical Trial for Acute Kidney Injury After Safety Review - Minichart
CalciMedica Announces Private Placement Financing for Up to About $49M to Advance Pulmonary Hypertension Program - Moomoo
CalciMedica Advances Auxora After Favorable FDA Safety Review - TipRanks
CalciMedica (Nasdaq: CALC) raises $15M, maps PAH and PH trial plans - Stock Titan
H.C. Wainwright Maintains CalciMedica(CALC.US) With Hold Rating - Moomoo
CalciMedica says FDA allows KOURAGE trial to continue - grafa.com
CalciMedica receives FDA clearance to continue Auxora trial By Investing.com - Investing.com Australia
CalciMedica, Inc. Announces Amendments to Loan and Warrant Agreements with Avenue Venture Opportunities Fund II, L.P – Minichart - Minichart
$CalciMedica (CALC.US)$ - Moomoo
What's Going On With CalciMedica Stock Wednesday?CalciMedica (NASDAQ:CALC) - Benzinga
CalciMedica secures up to $49M private placement financing - Investing.com
CalciMedica receives FDA clearance to continue Auxora trial - Investing.com
CalciMedica: Proceeds Expected to Support Pulmonary Hypertension Strategy, Including Phase 1b POC Study Evaluating Auxora in PAH, With Data Anticipated Mid-2027, and Advancement of Oral CRAC Channel Inhibitor CM5480 to IND Clearance Expecte - Moomoo
CalciMedica Says Auxora Phase 2 Trial May Continue Dosing After FDA Review - marketscreener.com
CalciMedica to Sell 18.7M Units >CALC - Moomoo
CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data - The AI Journal
CalciMedica Entered Into Definitive Securities Purchase Agreement With Leading Healthcare Investors >CALC - Moomoo
CalciMedica Amends Loan, Issues New Equity Warrants - TipRanks
Calcimedica Announces Private Placement Financing For Up To Approximately $49 Million To Advance Pulmonary Hypertension Program - TradingView
CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program - 富途牛牛
CalciMedica Extends $10M Loan, Adds $3M Conversion; Issues New $1.00 Warrants - TradingView
CalciMedica (NASDAQ: CALC) extends Avenue loan and issues new $1.00 warrants - Stock Titan
CALC News | CALCIMEDICA INC (NASDAQ:CALC) - ChartMill
Finanzdaten der Calcimedica Inc-Aktie (CALC)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):